Logo

ALZN

Alzamend Neuro, Inc.

ALZN

Alzamend Neuro, Inc. • NASDAQ
$2.12 ▼ -5.36% (-0.12)
Market Cap $6.66 M
52w High $12.06
52w Low $1.88
Dividend Yield 0%
P/E -1.8
Volume 49.93K
Outstanding Shares 3.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $2.7M ▲ $-2.703M ▼ 0% $-1.28 ▲ $-2.7M ▼
Q4-2025 $0 $1.126M ▲ $-1.139M ▼ 0% $-2.22 ▼ $-1.126M ▼
Q3-2025 $0 $1.037M ▼ $-1.039M ▲ 0% $-0.19 ▲ $-1.025M ▲
Q2-2025 $0 $1.358M ▲ $-1.362M ▼ 0% $-0.4 ▲ $-1.345M ▼
Q1-2025 $0 $962.405K $-974K 0% $-1.25 $-950K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $5.621M ▲ $6.327M ▲ $983.311K ▲ $5.343M ▲
Q3-2025 $3.358M ▼ $4.176M ▼ $725.851K ▼ $3.45M ▼
Q2-2025 $4.093M ▲ $5.008M ▲ $1.255M ▼ $3.753M ▲
Q1-2025 $1.194M ▲ $1.67M ▲ $2.882M ▼ $-1.212M ▲
Q4-2024 $376.048K $631.588K $3.226M $-2.594M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-2.703M ▼ $-2.363M ▼ $0 ▲ $4.035M ▲ $1.672M ▲ $-2.363M ▼
Q4-2025 $-1.139M ▼ $-688.705K ▲ $-210K ▼ $1.489M ▲ $590.523K ▲ $-898.705K ▲
Q3-2025 $-985.783K ▲ $-1.424M ▲ $0 $688.7K ▼ $-734.938K ▼ $-1.424M ▲
Q2-2025 $-1.415M ▼ $-3.4M ▼ $0 ▲ $6.299M ▲ $2.899M ▲ $-3.31M ▼
Q1-2025 $-974.411K $-1.056M $-90K $1.964M $817.902K $-1.146M

Five-Year Company Overview

Income Statement

Income Statement Alzamend Neuro is still a pure research‑stage biotech with no product sales yet. All of its reported results come from research and corporate overhead, so the company consistently posts losses as it funds trials and development. The earnings per share trends mainly reflect accounting effects and repeated reverse stock splits rather than a sudden change in the underlying business. Overall, this is an early‑stage story where spending today is aimed at possible future products, not current profitability.

Balance Sheet

Balance Sheet The balance sheet is very light: minimal assets, very little cash, no meaningful debt, and only a thin layer of shareholder equity. This suggests limited financial cushion and a strong dependence on raising new capital from investors to keep funding operations. The series of reverse stock splits over recent years also hints at pressure on the share price and a need to preserve access to equity markets. On the positive side, the lack of debt reduces financial leverage risk, but it does not solve the core challenge of funding ongoing R&D.

Cash Flow

Cash Flow Cash flows show a steady pattern: money going out for operations and essentially nothing coming in from products. Free cash flow is consistently negative, reflecting the cost of running clinical trials and the broader business. There is no real spending on long‑term physical assets; nearly all cash use is for people, research, and regulatory work. This means the company’s ability to continue at its current pace depends heavily on fresh financing, likely through issuing equity or forming partnerships.

Competitive Edge

Competitive Edge Alzamend’s competitive position leans more on future potential than current market presence. It operates in highly crowded and well‑funded areas—Alzheimer’s and psychiatric disorders—where large pharmaceutical companies are active. The company’s edge lies in its differentiated approaches: a redesigned lithium formulation that aims to be safer and easier to use, and a personalized, cell‑based Alzheimer’s vaccine. Strong licensing agreements and patent protection into the 2030s help create a legal moat, but the firm is still small and will likely face intense competition from much larger players if its products reach late‑stage development or the market.

Innovation and R&D

Innovation and R&D Innovation is the core of Alzamend’s value proposition. AL001 tries to re‑engineer lithium therapy so patients can potentially get brain benefits with fewer systemic side effects and less burdensome monitoring, which, if proven, could be a meaningful improvement over today’s standard treatments. ALZN002 takes a cutting‑edge immunotherapy route, using a patient’s own immune cells to target Alzheimer’s‑related proteins, aiming for a more durable and possibly safer response than traditional antibody drugs. Both candidates are at relatively early to mid clinical stages, so there is still significant scientific and regulatory risk, but the concepts are clearly differentiated and backed by exclusive licenses and patents.

Summary

Alzamend Neuro is a very early‑stage biotech without revenue, running persistent operating losses and relying on external funding to support its business. Its balance sheet and cash flows indicate a limited financial buffer and ongoing need for capital, as reflected in repeated reverse stock splits. The company’s main strengths are its innovative drug platforms in major disease areas, backed by long‑dated intellectual property and university‑based science. At the same time, it operates in highly competitive therapeutic fields and still needs to validate its technologies through larger, riskier clinical trials. The overall picture is of a high‑uncertainty, research‑driven company whose future will depend heavily on upcoming clinical results, regulatory progress, and its ability to secure partnerships or financing.

NEWS

November 19, 2025 · 8:00 AM UTC

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Read more